4-(4-fluorophenyl)-5-(4-methylsulfonyl)phenyl-2H-pyridazin-3-one | 213764-17-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-(4-fluorophenyl)-5-(4-methylsulfonyl)phenyl-2H-pyridazin-3-one
• 英文别名: 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone；4-(4-Fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-2-hydropyridazin-3-one；5-(4-fluorophenyl)-4-(4-methylsulfonylphenyl)-1H-pyridazin-6-one
• CAS: 213764-17-1
• 化学式: C₁₇H₁₃FN₂O₃S
• 分子量: 344.366
• InChiKey: ZMCKLPPZCCJCBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  84
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(4-fluorophenyl)-5-(4-methylsulfonyl)phenyl-2H-pyridazin-3-one 在 diisopropyl (E)-azodicarboxylate 作用下， 以 乙酸乙酯 、 甲苯 为溶剂， 生成 2-(1-Methylcyclopentyl)-4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone
  参考文献：
  名称：

  Prostaglandin endoperoxide H synthase biosynthesis inhibitors

  摘要：

  该发明描述了式I的吡啶并酮化合物，这些化合物是环氧合酶（COX）抑制剂，特别是选择性地抑制环氧合酶-2（COX-2）。COX-2是与炎症相关的可诱导异构体，与构成性异构体环氧合酶-1（COX-1）相对，后者是许多组织中重要的“基础”酶，包括胃肠道（GI）和肾脏。这些化合物对COX-2的选择性减少了目前市售的非甾体类抗炎药（NSAIDs）所见到的不良胃肠道和肾脏副作用。

  公开号：

  US06307047B1
• 作为产物：
  描述：

  5-(4-methylsulfonyl)phenyl-4-phenyl-2H-pyridazin-3-one 生成 4-(4-fluorophenyl)-5-(4-methylsulfonyl)phenyl-2H-pyridazin-3-one
  参考文献：
  名称：

  US6004960

  摘要：

  公开号：

文献信息

• Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
  申请人：——

  公开号：US20010041726A1

  公开（公告）日：2001-11-15

  The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent, such as, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B 4 (LTB 4 ) receptor antagonists, leukotriene A 4 (LTA 4 ) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.

  本发明描述了新颖的硝化和/或亚硝化环氧合酶2（COX-2）抑制剂以及包含至少一种硝化和/或亚硝化环氧合酶2（COX-2）抑制剂的新型组合物，以及可选地，至少一种捐赠、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮源性舒张因子水平或是一氧化氮合酶底物的化合物，和/或可选地，至少一种治疗剂，如类固醇、非甾体抗炎化合物（NSAID）、5-脂氧合酶（5-LO）抑制剂、白三烯B4（LTB4）受体拮抗剂、白三烯A4（LTA4）水解酶抑制剂、5-HT激动剂、3-羟基-3-甲基戊二酰辅酶A（HMGCoA）抑制剂、H受体拮抗剂、抗肿瘤药物、抗血小板药物、解充血剂、利尿剂、镇静或非镇静抗组胺药、诱导型一氧化氮合酶抑制剂、阿片类药物、镇痛剂、幽门螺杆菌抑制剂、质子泵抑制剂、异前列腺素抑制剂以及其混合物。本发明还提供了包含至少一种母体COX-2抑制剂和至少一种一氧化氮供体的新型组合物，以及可选地，至少一种治疗剂。本发明还提供了用于治疗炎症、疼痛和发热的工具和方法；用于治疗和/或改善COX-2抑制剂的胃肠道特性；用于促进伤口愈合；用于治疗和/或预防肾毒性；以及用于治疗和/或预防由于环氧合酶-2水平升高而导致的其他疾病的工具和方法。
• [EN] PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS<br/>[FR] INHIBITEURS DE LA BIOSYNTHESE DE LA PROSTAGLANDINE ENDOPEROXYDE H SYNTHASE
  申请人：ABBOTT LAB

  公开号：WO2000024719A1

  公开（公告）日：2000-05-04

  The present invention describes pyridazinone compounds of formula (I) which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important 'housekeeping' enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectively of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

  本发明描述了式（I）的吡啶酮化合物，它们是环氧合酶（COX）抑制剂，特别是选择性抑制剂环氧合酶-2（COX-2）。COX-2是与炎症有关的诱导型同工酶，而非构成型同工酶环氧合酶-1（COX-1），后者是许多组织（包括胃肠道和肾脏）中重要的“管家”酶。这些化合物对COX-2的选择性最小化了目前市场上非甾体类抗炎药（NSAIDs）所见的不良胃肠道和肾脏副作用。
• [EN] NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE<br/>[FR] INHIBITEURS DE CYCLOOXYGENASE-2 NITROSES ET NITROSYLES, COMPOSITIONS ET PROCEDES D'UTILISATION
  申请人：NITROMED INC

  公开号：WO2001045703A1

  公开（公告）日：2001-06-28

  The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound taht donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent, such as, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B4 (LTB4) receptor antagonists, leukotriene A4 (LTA4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H2 antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.

  本发明描述了新型的硝化和/或亚硝化环氧合酶2（COX-2）抑制剂，以及包含至少一种硝化和/或亚硝化环氧合酶2（COX-2）抑制剂的新型组合物，并且，可选地，包含至少一种捐赠、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮衍生松弛因子水平或是一氧化氮合酶底物的化合物，以及/或可选的至少一种治疗剂，例如类固醇、非甾体抗炎化合物（NSAID）、5-脂氧合酶（5-LO）抑制剂、白三烯B4（LTB4）受体拮抗剂、白三烯A4（LTA4）水解酶抑制剂、5-HT激动剂、3-羟基-3-甲基戊二酸辅酶A（HMG-CoA）抑制剂、H2受体拮抗剂、抗肿瘤剂、抗血小板剂、除充血剂、利尿剂、镇静或非镇静型抗组胺药、诱导型一氧化氮合酶抑制剂、阿片类药物、镇痛剂、幽门螺杆菌抑制剂、质子泵抑制剂、异前列腺素抑制剂以及其混合物。本发明还提供包含至少一种母体COX-2抑制剂和至少一种一氧化氮供体的新型组合物，以及/或可选的至少一种治疗剂。本发明还提供用于治疗炎症、疼痛和发热的工具和方法；用于治疗和/或改善COX-2抑制剂的胃肠道特性；用于促进伤口愈合的工具和方法；用于治疗和/或预防肾毒性的工具和方法；以及用于治疗和/或预防由于环氧合酶-2水平升高而引起的其他疾病的工具和方法。
• [EN] PYRIDAZINONES AS INHIBITORS OF CYCLOOXYGENASE-2<br/>[FR] PYRIDAZINONES UTILISES COMME INHIBITEURS DE CYCLO-OXYGENASE-2
  申请人：MERCK FROSST CANADA & CO.

  公开号：WO1998041511A1

  公开（公告）日：1998-09-24

  (EN) The invention encompasses the pyridazin-3-one compounds of formula (I) as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of formula (I). The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of formula (I).(FR) L'invention se rapporte à des composés de pyridazine-3-one, représentés par la formule (I), et à un procédé de traitement de maladies à médiation par cyclo-oxygénase-2. Le procédé consiste à administrer une quantité non toxique et pharmaceutiquement efficace d'un composé de formule I à un patient nécessitant un tel traitement. L'invention concerne également certaines compositions pharmaceutiques destinées au traitement de maladies à médiation par cyclo-oxygénase-2, qui contiennent des composés de formule (I).

  该发明涉及公式（I）的吡啶并嗪-3-酮化合物，以及一种治疗环氧合酶-2介导疾病的方法，该方法包括向需要此类治疗的患者施用公式（I）化合物的非毒性治疗有效量。该发明还涵盖了某些用于治疗环氧合酶-2介导疾病的药物组合物，其中包括公式（I）化合物。
• NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE
  申请人：BANDARAGE Ramani R.

  公开号：US20090099139A1

  公开（公告）日：2009-04-16

  The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.

  本发明描述了新型的亚硝酸化和/或亚硝基化环氧合酶2（COX-2）抑制剂，以及包含至少一种亚硝酸化和/或亚硝基化环氧合酶2（COX-2）抑制剂的新型组合物，可选择地包含至少一种捐赠、转移或释放一氧化氮、刺激内源性合成一氧化氮、提高内源性内皮衍生松弛因子水平或是一氧化氮合酶底物的化合物，以及/或可选择地包含至少一种治疗剂。本发明还提供了包含至少一种母体COX-2抑制剂和至少一种一氧化氮供体的新型组合物，可选择地包含至少一种治疗剂。本发明还提供了用于治疗炎症、疼痛和发热的套件和方法；用于治疗和/或改善COX-2抑制剂的胃肠道特性；用于促进伤口愈合；用于治疗和/或预防肾毒性；以及用于治疗和/或预防由于升高的环氧合酶-2水平而引起的其他疾病的方法。